David Lebowitz

GW Pharma Analysts Raise Estimates After CBD Drug Epidiolex Shows Strong Uptake

Ionis Wins Price Target Hike On Partner Biogen's Guidan

Morgan Stanley: DEA Likely To Reclassify GW Pharma's Cannabinoid Therapy For US Launch

Ionis Wins Price Target Hike On Partner Biogen's Guidan

Morgan Stanley: DEA Likely To Reclassify GW Pharma's Cannabinoid Therapy For US Launch

Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

Newly Public Gene Therapy Biotech Avrobio Picks Up Two Sell-Side Bulls

Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

|

Newly Public Gene Therapy Biotech Avrobio Picks Up Two Sell-Side Bulls

|

Unity Biotech Is A Buy On 'Novel Biology,' Morgan Stanley Says In Positive Initiation

|

Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate

|

David Lebowitz Recent News

Insmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan Stanley

|

Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy

|

As Celgene Outperforms, Are Challenges To Its Pipeline Being Overlooked?

|

Sarepta's Upside Story Is Just Getting Started

|

Data Monitoring Committee Determines Alnylam's ENDEAVOUR Trial May Continue

|

Raptor Pharmaceuticals Buys Quinsair: What You Need To Know

|